American Century Companies’s Context Therapeutics CNTX Stock Holding History

American Century Companies’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50,912	Closed	-$133K	–	2906
2026 Q1	$133K	Buy	+50,912	New	+$119K	﹤0.01%	2755

Other funds holding CNTX

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

American Century Companies's CNTX Position: Q2 2026 in Review

American Century Companies sold out of Context Therapeutics (CNTX) in Q2 2026, closing a stake of 50,912 shares — an estimated $133K sold.

American Century Companies first reported a position in CNTX in Q1 2026 and held it in 1 quarter. The position peaked at $133K in Q1 2026. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

American Century Companies reported no remaining Context Therapeutics position as of Q2 2026 after selling out during the quarter.
American Century Companies sold 50,912 Context Therapeutics shares in Q2 2026, an estimated $133K.
American Century Companies first reported a position in Context Therapeutics in Q1 2026 and held it in 1 quarter.
American Century Companies's Context Therapeutics position peaked at $133K in Q1 2026.
79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.